drugset / Trial / NCT05084196

Melatonin for Prevention of Kidney Injury

NCT05084196

Phase 3 Recruiting 300 enrolled Rutgers, The State University of New Jersey
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.

Timeline

Start
2023-06-05
Primary completion
2027-06-01
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 5 mg Oral

Indications